Octreotide
- Generic Name
- Octreotide
- Brand Names
- Bynfezia, Mycapssa, Sandostatin
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 83150-76-9
- Unique Ingredient Identifier
- RWM8CCW8GP
- Background
Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may also occur. Acromegaly is a life-threat...
- Indication
Octreotide by injection is used for the treatment of acromegaly and the reduction of flushing and diarrhea symptoms related to carcinoid tumors and/or vasoactive intestinal peptide (VIPoma) tumors. The delayed-release oral formulation is used for the long-term treatment of acromegaly in patients who tolerate and respond adequately to injectable octreotide an...
- Associated Conditions
- Acromegaly, Diarrhea, Metastatic Carcinoid Tumors
- Associated Therapies
- Long-term maintenance therapy
Etiology, Assessment and Treatment of Post-gastric Bypass Severe Hypoglycemia
- Conditions
- Interventions
- First Posted Date
- 2013-05-31
- Last Posted Date
- 2019-10-28
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 33
- Registration Number
- NCT01865760
- Locations
- 🇩🇰
Department of Endocrinology, Aarhus University Hospital, Aarhus C, Denmark
Ghrelin Suppression by Octreotide in Prader-Willi
- Conditions
- Interventions
- First Posted Date
- 2012-06-07
- Last Posted Date
- 2022-12-16
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 2
- Registration Number
- NCT01613495
Midodrine, Octreotide and Albumin: Impact on Renal Function of Patients With Liver Cirrhosis and Renal Failure
- Conditions
- Interventions
- First Posted Date
- 2012-04-30
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Anna Cruceta
- Registration Number
- NCT01587222
- Locations
- 🇪🇸
Hospital Clinic i Provincial de Barcelona, Barcelona, Spain
Autologous Fibrin Glues for Fistulas Closure
- Conditions
- Interventions
- First Posted Date
- 2012-03-22
- Last Posted Date
- 2013-02-26
- Lead Sponsor
- Jinling Hospital, China
- Target Recruit Count
- 122
- Registration Number
- NCT01561066
- Locations
- 🇨🇳
Department of Surgery, Jinling Hospital, Nanjing, Jiangsu, China
Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly
- First Posted Date
- 2011-02-14
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- Endo Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT01295060
Comparison of Terlipressin, Somatostatin, and Octreotide for Control of Variceal Bleeding
- Conditions
- Interventions
- First Posted Date
- 2009-08-26
- Last Posted Date
- 2018-03-19
- Lead Sponsor
- Korea University
- Target Recruit Count
- 1034
- Registration Number
- NCT00966355
- Locations
- 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of
Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome
- First Posted Date
- 2009-04-21
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- Endo Pharmaceuticals
- Target Recruit Count
- 10
- Registration Number
- NCT00884715
Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease
- Conditions
- Interventions
- First Posted Date
- 2008-06-04
- Last Posted Date
- 2013-07-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 186
- Registration Number
- NCT00690430
- Locations
- 🇺🇸
University of Arizona / Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Scottsdale Healthcare/TGen Clinical Research Service TGen Clinical Research Service, Scottsdale, Arizona, United States
🇺🇸Loma Linda University Dept. of Loma Linda CancerCent, Loma Linda, California, United States
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
- First Posted Date
- 2008-01-25
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 358
- Registration Number
- NCT00600886
- Locations
- 🇬🇧
Novartis Investigative Site, Southampton, United Kingdom
🇺🇸Johns Hopkins University School of Medicine Dept.ofJohnsHopkinsUniv., Baltimore, Maryland, United States
🇺🇸University of Michigan Comprehensive Cancer Center Deptof Endocrinology&Diabetes, Ann Arbor, Michigan, United States
The Safety & Efficacy of Terlipressin vs Octreotide for the Control of Variceal Bleed
- Conditions
- Interventions
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2007-12-05
- Lead Sponsor
- Aga Khan University
- Target Recruit Count
- 320
- Registration Number
- NCT00534677
- Locations
- 🇵🇰
The Aga Khan University Hospital, Karachi, Sindh, Pakistan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.